The Ghent laboratory group anacura announces the acquisition of OHMX.bio, a spin-off from Ghent University specialized in -omics technology. In addition to the existing medical and pharmaceutical analytical activities of the two current anacura companies, Labo Nuytinck and AnaBioTec, OHMX.bio will expand the expertise within the group with multi-omics for innovative and exploratory drug research and diagnostics.
SUMMARY
- The Ghent laboratory group anacura announces the acquisition of OHMX.bio, a spin-off from Ghent University specialized in -omics technology.
- Founded in 1985, anacura is an independent analytical centre of excellence in healthcare and drug development.
Read also - ENEIDA.IO funding news – Coimbra-based ENEIDA.IO Raises €10.5 Million in Series B Round Funding
Anacura is an independent analytical laboratory active in the healthcare and pharmaceutical industry. The group informs doctors and patients with reliable and high-quality laboratory medicine under the flag of Labo Nuytinck and also offers customized analytical solutions for pharmaceutical and biotech companies via AnaBioTec. OHMX.bio now joins the group as a third subsidiary.
Read also - SmartCap invests €5M in Antler Nordic Fund II
RECOMMENDED FOR YOU
Logically acquisition news – London-based Logically Acquired Insikt AI
Team SR
Aug 20, 2024
Engelhart Acquisition news – London-based Engelhart Acquired Trailstone
Team SR
Aug 26, 2024
Anacura CEO Griet Nuytinck: “With the acquisition of OHMX.bio, we want to further strengthen our position as a leader in biomedical analysis. The acquisition fits within our overarching strategy to further expand our service offering towards innovative and exploratory research and diagnostics. OHMX.bio shares our mission and values, and together we will be able to make an even stronger contribution to Belgian biotech and far beyond.”
OHMX.bio CEO Gerben Menschaert is convinced that the company is the perfect addition to anacura's current portfolio. Menschaert is one of the co-founders of OHMX.bio and is still affiliated as a professor at the Lab for Bioinformatics and Computational Genomics at Ghent University.
“The acquisition of OHMX.bio by anacura ensures a stronger future for both parties,” he says. “OHMX.bio can enter new markets and reach new customers, and anacura expands its offering of innovative technologies. Furthermore, we share the same drive for top quality, groundbreaking science and a personal approach tailored to each project. Together, we strengthen anacura's unique position as a one-stop-shop for advanced biochemical analyses within the Ghent biotech landscape.”
About anacura
Founded in 1985, anacura is an independent analytical centre of excellence in healthcare and drug development. Your go-to provider for top quality laboratory solutions delivered with a great human touch.Anacura is an independent analytical laboratory active in the healthcare and pharmaceutical industry. The group informs doctors and patients with reliable and high-quality laboratory medicine under the flag of Labo Nuytinck and also offers customized analytical solutions for pharmaceutical and biotech companies via AnaBioTec. OHMX.bio now joins the group as a third subsidiary.
About OHMX.bio
Founded in 2019, OHMX.Bio provides a complete R&D platform to help customers resolve their biological questions through cutting-edge technologies in different -omics fields: (epi)genomics, transcriptomics, translatomics and proteomics. Current flagships in portfolio are ribosome profiling and third generation sequencing.